JPH07505608A - インターロイキン−1阻害化合物による神経病学的状態の治療 - Google Patents
インターロイキン−1阻害化合物による神経病学的状態の治療Info
- Publication number
- JPH07505608A JPH07505608A JP5508260A JP50826093A JPH07505608A JP H07505608 A JPH07505608 A JP H07505608A JP 5508260 A JP5508260 A JP 5508260A JP 50826093 A JP50826093 A JP 50826093A JP H07505608 A JPH07505608 A JP H07505608A
- Authority
- JP
- Japan
- Prior art keywords
- effective
- treatment
- administered
- use according
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (26)
- 1.神経病学的偏異の状態の治療用の有効な薬剤として、インターロイキン−1 の作用を防御、阻害または修正する化合物の使用。
- 2.有効な薬剤が、インターロイキン−1レセプター拮抗体、好ましくはインタ ーロイキン−1レセプター拮抗体蛋白(便利には“IL−lra”として参照さ れた)である請求の範囲1に記載の使用。
- 3.IL−lraが、組み替えIL−lraである請求の範囲2に記載の使用。
- 4.有効な薬剤が、IL−lraの断片または誘導体である請求の範囲1に記載 の使用。
- 5.有効な薬剤が、合成IL−lraまたはこれの断片または誘導体である請求 の範囲1に記載の使用。
- 6.投与された有効な薬剤の量および/または濃度が、作用の部位において、1 00〜10000μgの範囲(好ましくは1000〜5000μgそして特に約 2400μgの範囲)で、インターロイキン−1拮抗体の量を与えるように、体 重80kgの患者を基準として計算される請求の範囲1〜5のいずれかに記載の 使用。
- 7.有効な薬剤の分子量が、約40KDa(キロダルトン)までである請求の範 囲1〜6のいずれかに記載の使用。
- 8.有効な薬剤の分子量が、5〜25KDaの範囲、特に15〜20KDaの範 囲にある請求の範囲7に記載の使用。
- 9.有効な薬剤が、同定された、または疑われた神経一偏異の部位に、例えば注 射により直接導入されることにより投与される請求の範囲1〜8のいずれかに記 載の使用。
- 10.有効な薬剤が、間接法、例えば体内で導入の部位から、次に必要とされ且 つ効果を有すべき部位に移転することができるように末梢部位に導入することに より投与される請求の範囲1〜8のいずれかに記載の使用。
- 11.有効な薬剤が、例えば静脈注射により血流を通って移転させることにより 投与される請求の範囲10に記載の使用。
- 12.有効な薬剤が、脳−脊髄液を通って移転させることにより投与される請求 の範囲10に記載の使用。
- 13.脳の状態の治療、特に脳の神経単位の治療に適用される請求の範囲1〜1 2のいずれかに記載の使用。
- 14.有効な薬剤が、頭蓋内空洞に投与される請求の範囲1〜13のいずれかに 記載の使用。
- 15.有効な薬剤が、薬学的に受入れ可能な担体(溶媒または希釈剤)に分散ま たは溶解する処方として使用される請求の範囲1〜14のいずれかに記載の使用 。
- 16.処方が、水または水性媒質、特に正常な食塩水(水中に塩化ナトリウムの 等張溶液)中にある請求の範囲15に記載の使用。
- 17.有効な薬剤が、連続投与により投与される請求の範囲1〜16のいずれか に記載の使用。
- 18.虚血性状態にある神経−偏異、例えば種々の形の脳損傷を包含し、且つ脳 神経単位に対する急性または遅延した損傷および例えば頭部障害後の偏異に導く 脳性虚血(発作、出血または障害の結果としての脳障害)、の治療に適用される 請求の範囲1〜14のいずれかに記載の使用。
- 19.非虚血性起源の相対的に長期の神経−偏異(例えば癲癇、ハンチングトン 舞踏病、ダウン症候群およびパーキンソン病)の治療に適用する請求の範囲1〜 17のいずれかに記載の使用。
- 20.アルツハイマー病の治療のための請求の範囲19に記載の使用。
- 21.有効な薬剤が、例えば患者または主体が虚血性状態の危険あると考えられ る場合に、予防治療として虚血性状態の前に投与される請求の範囲1〜19のい ずれかに記載の使用。
- 22.有効な薬剤が、例えば発作を治療する状態におけるような虚血性損傷が生 じるか、または疑われる後、そして好ましくは、その後可及的速やかに投与され る請求の範囲1〜16のいずれかに記載の使用。
- 23.ベーターアミロイド蛋白(ベーターAP)の、特に例えば血小板のような 沈着した形での、形成の減少に適用される請求の範囲1〜22のいずれかに記載 の使用。
- 24.毒性刺激性の脳損傷の治療のための請求の範囲1〜17のいずれかに記載 の使用。
- 25.本明細書中に記載された如く、薬学的に受入れ可能な担体(溶媒または希 釈剤)、特に水または水性媒質、特に正常な食塩水(水中に塩化ナトリウムの等 張溶液)に分散または溶解する有効な薬剤からなる請求の範囲1〜23のいずれ かに記載の使用。
- 26.有効な薬剤としてインターロイキン−1の作用を防御、阻害または修正す る化合物を投与することからなるヒトまたは動物患者における神経病学的偏異状 態を治療する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919123161A GB9123161D0 (en) | 1991-10-31 | 1991-10-31 | Treatment of neurological conditions |
GB9123161.3 | 1991-10-31 | ||
GB919125670A GB9125670D0 (en) | 1991-11-30 | 1991-11-30 | Treatment of neurogical conditions |
GB9125670.1 | 1991-11-30 | ||
PCT/GB1992/002023 WO1993008820A1 (en) | 1991-10-31 | 1992-11-02 | Treatment of neurological conditions by an interleukin-1 inhibiting compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07505608A true JPH07505608A (ja) | 1995-06-22 |
JP3623501B2 JP3623501B2 (ja) | 2005-02-23 |
Family
ID=26299779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50826093A Expired - Lifetime JP3623501B2 (ja) | 1991-10-31 | 1992-11-02 | インターロイキン−1阻害化合物による神経病学的状態の治療 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6090775A (ja) |
EP (1) | EP0610336B1 (ja) |
JP (1) | JP3623501B2 (ja) |
AT (1) | ATE214939T1 (ja) |
AU (3) | AU2884592A (ja) |
CA (1) | CA2122596C (ja) |
DE (1) | DE69232516T2 (ja) |
DK (1) | DK0610336T3 (ja) |
ES (1) | ES2173871T3 (ja) |
WO (2) | WO1993008819A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
EP0779074B1 (en) * | 1995-04-07 | 2004-07-07 | Teijin Limited | Protective agent for organ or tissue |
US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
US20030040660A1 (en) * | 2001-08-27 | 2003-02-27 | George Jackowski | Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein |
AU2002332931A1 (en) * | 2001-09-06 | 2003-03-24 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
CN101133084A (zh) * | 2004-12-02 | 2008-02-27 | 多曼蒂斯有限公司 | 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法 |
CN101466734A (zh) * | 2005-12-01 | 2009-06-24 | 杜门蒂斯有限公司 | 与白细胞介素-1受体1型结合的竞争性域抗体形式 |
EP2385839B1 (en) * | 2009-01-09 | 2014-11-26 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of corneal disorders |
CN107337735B (zh) | 2010-07-29 | 2021-06-22 | 巴扎德制药公司 | 嵌合il-1受体i型激动剂和拮抗剂 |
BR112015022587A2 (pt) | 2013-03-13 | 2017-10-24 | Eleven Biotherapeutics Inc | formulações de citocina quimérica para entrega ocular |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL100533A (en) * | 1986-12-31 | 1994-05-30 | Hoechst Roussel Pharma | Pharmaceutical preparations containing a history of xanthine for VIH treatment and disease states |
US4965271A (en) * | 1986-12-31 | 1990-10-23 | Hoechst Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
HU203198B (en) * | 1987-10-26 | 1991-06-28 | Sandoz Ag | Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect |
CA2058952A1 (en) * | 1989-06-13 | 1990-12-14 | Nabil Hanna | Monokine activity interference |
AU649245B2 (en) * | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
-
1992
- 1992-11-02 ES ES92922537T patent/ES2173871T3/es not_active Expired - Lifetime
- 1992-11-02 WO PCT/GB1992/002019 patent/WO1993008819A1/en active Application Filing
- 1992-11-02 CA CA002122596A patent/CA2122596C/en not_active Expired - Lifetime
- 1992-11-02 US US08/232,167 patent/US6090775A/en not_active Expired - Lifetime
- 1992-11-02 AU AU28845/92A patent/AU2884592A/en not_active Abandoned
- 1992-11-02 AT AT92922537T patent/ATE214939T1/de not_active IP Right Cessation
- 1992-11-02 DK DK92922537T patent/DK0610336T3/da active
- 1992-11-02 AU AU28041/92A patent/AU2804192A/en not_active Abandoned
- 1992-11-02 JP JP50826093A patent/JP3623501B2/ja not_active Expired - Lifetime
- 1992-11-02 WO PCT/GB1992/002023 patent/WO1993008820A1/en active IP Right Grant
- 1992-11-02 EP EP92922537A patent/EP0610336B1/en not_active Expired - Lifetime
- 1992-11-02 DE DE69232516T patent/DE69232516T2/de not_active Expired - Lifetime
-
1996
- 1996-12-24 AU AU76482/96A patent/AU7648296A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK0610336T3 (da) | 2002-07-22 |
DE69232516T2 (de) | 2002-10-31 |
AU2884592A (en) | 1993-06-07 |
DE69232516D1 (de) | 2002-05-02 |
WO1993008819A1 (en) | 1993-05-13 |
US6090775A (en) | 2000-07-18 |
JP3623501B2 (ja) | 2005-02-23 |
EP0610336A1 (en) | 1994-08-17 |
ES2173871T3 (es) | 2002-11-01 |
CA2122596C (en) | 2008-06-03 |
ATE214939T1 (de) | 2002-04-15 |
AU2804192A (en) | 1993-06-07 |
EP0610336B1 (en) | 2002-03-27 |
AU7648296A (en) | 1997-02-13 |
CA2122596A1 (en) | 1993-05-13 |
WO1993008820A1 (en) | 1993-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kuehn et al. | Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. | |
KR100343314B1 (ko) | 만성통증치료에유용한레보부피바카인 | |
Zhou et al. | PPARγ activation mitigates mechanical allodynia in paclitaxel-induced neuropathic pain via induction of Nrf2/HO-1 signaling pathway | |
JP2011079860A (ja) | 脳虚血の処置法及び脳虚血の処置のためのエリスロポエチン又はエリスロポエチン誘導体類の使用 | |
Russo et al. | Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury | |
RU2095060C1 (ru) | Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний | |
JP2015522630A (ja) | 多発性硬化症治療のためのビオチンの使用 | |
Glybina et al. | Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide | |
JPH07505608A (ja) | インターロイキン−1阻害化合物による神経病学的状態の治療 | |
EP2464229A1 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
CA3124499A1 (en) | Method for treating parkinson's disease by administering resiniferatoxin | |
EP1669078A1 (en) | Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside RB 1 | |
van de Meent et al. | Beneficial effects of the melanocortin α-melanocyte-stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury | |
Cadichon et al. | Neuroprotective effect of the surfactant poloxamer 188 in a model of intracranial hemorrhage in rats | |
RU2485956C2 (ru) | Новая композиция для лечения побочных эффектов противораковой терапии | |
KR20000075895A (ko) | 편두통 치료에서의 레보부피바카인 또는 로피바카인의 용도 | |
RU2721282C2 (ru) | Способ лечения рассеянного склероза (варианты) | |
DE60028787T2 (de) | Methode zur behandlung von verletzungen des traumatisierten gehirns mit nicht-steroid entzündungshemmenden medikamenten | |
KR101936836B1 (ko) | 허혈성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
DE60012183T2 (de) | Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen | |
DE60019166T2 (de) | Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen | |
Asadi-Pooya et al. | Potentiation of anti-epileptic drugs effectiveness by pyronaridine in refractory epilepsy | |
DE2908127A1 (de) | Verwendung von inhibitoren des abbaus von enkephalinen und endorphinen bei der bekaempfung von schmerzzustaenden sowie zur herstellung pharmazeutischer zubereitungen und arzneimittel | |
TWI581790B (zh) | 一種化合物用於製備治療視神經之醫藥組合物的用途 | |
KR20130092470A (ko) | 서브스턴스-p를 포함하는 신경병증성 통증 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040602 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040624 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041027 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041125 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 3 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 3 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 3 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071203 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081203 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091203 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101203 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111203 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111203 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121203 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term |